Since the online publication of this article, the authors have noticed that their funding statement in incorrect. The correct funding statement is ‘This study was supported by National Cancer Institute grants to the Gynecologic Oncology GroupAdministrative Office, NRG Oncology Statistics and Data Management Center (U10 CA180822) and NRGOncology Operations Center (U10CA180868).’
. Author manuscript; available in PMC: 2022 Jan 12.
Published in final edited form as: Int J Gynecol Cancer. 2020 May 4;30(7):1084. doi: 10.1136/ijgc-2019-001012corr1
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Jyoti Mayadev
1, Dmitriy Zamarin
2, Wei Deng
3, Heather Lankes
4, Roisin O’Cearbhaill
2, Carol A Aghajanian
2, Russell Schilder
5
Jyoti Mayadev
1Department of Radiation Medicine and Applied Sciences,
University of California San Diego Medical Center, La Jolla, California, USA
Find articles by Jyoti Mayadev
Dmitriy Zamarin
2Department of Medical Oncology, Memorial Sloan Kettering
Cancer Center, New York City, New York, USA.
Find articles by Dmitriy Zamarin
Wei Deng
3Department of Biostatistics and Bioinformatics, NRG
Oncology, Clinical Trial Development Division, Buffalo, New York, USA.
Find articles by Wei Deng
Heather Lankes
4Biopathology Center, The Research Institute at Nationwide
Children’s Hospital, Columbus, Ohio, USA.
Find articles by Heather Lankes
Roisin O’Cearbhaill
2Department of Medical Oncology, Memorial Sloan Kettering
Cancer Center, New York City, New York, USA.
Find articles by Roisin O’Cearbhaill
Carol A Aghajanian
2Department of Medical Oncology, Memorial Sloan Kettering
Cancer Center, New York City, New York, USA.
Find articles by Carol A Aghajanian
Russell Schilder
5Department of Medical Oncology, Thomas Jefferson
University, Philadelphia, Pennsylvania, USA.
Find articles by Russell Schilder
1Department of Radiation Medicine and Applied Sciences,
University of California San Diego Medical Center, La Jolla, California, USA
2Department of Medical Oncology, Memorial Sloan Kettering
Cancer Center, New York City, New York, USA.
3Department of Biostatistics and Bioinformatics, NRG
Oncology, Clinical Trial Development Division, Buffalo, New York, USA.
4Biopathology Center, The Research Institute at Nationwide
Children’s Hospital, Columbus, Ohio, USA.
5Department of Medical Oncology, Thomas Jefferson
University, Philadelphia, Pennsylvania, USA.
✉
jmayadev@ucsd.edu.
Issue date 2020 Jul.
PMCID: PMC8753753 NIHMSID: NIHMS1596772 PMID: 32371424
The publisher's version of this article is available at Int J Gynecol Cancer
This corrects the article "Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer." on page 701.